首页> 外文期刊>Vaccine >Dual-chamber injection device for measles-rubella vaccine: The potential impact of introducing varying sizes of the devices in 3 countries
【24h】

Dual-chamber injection device for measles-rubella vaccine: The potential impact of introducing varying sizes of the devices in 3 countries

机译:用于麻疹-Surbella疫苗的双室注射装置:在3个国家引入不同尺寸的尺寸的潜在影响

获取原文
获取原文并翻译 | 示例
           

摘要

IntroductionBy pairing diluent with vaccines, dual-chamber vaccine injection devices simplify the process of reconstituting vaccines before administration and thus decrease associated open vial wastage and adverse events. However, since these devices are larger than current vaccine vials for lyophilized vaccines, manufacturers need guidance as to how the size of these devices may affect vaccine distribution and delivery.MethodsUsing HERMES-generated immunization supply chain models of Benin, Bihar (India), and Mozambique, we replace the routine 10-dose measles-rubella (MR) lyophilized vaccine with single-dose MR dual-chamber injection devices, ranging the volume-per-dose (5.2–26?cm3) and price-per-dose ($0.70, $1.40).ResultsAt a volume-per-dose of 5.2?cm3, a dual-chamber injection device results in similar vaccine availability, decreased open vial wastage (OVW), and similar total cost per dose administered as compared to baseline in moderately constrained supply chains. Between volumes of 7.5?cm3and 26?cm3, these devices lead to a reduction in vaccine availability between 1% and 14% due to increases in cold chain storage utilization between 1% and 7% and increases in average peak transport utilization between 2% and 44%. At the highest volume-per-dose, 26?cm3, vaccine availability decreases between 9% and 14%. The total costs per dose administered varied between each scenario, as decreases in vaccine procurement costs were coupled with decreases in doses administered. However, introduction of a dual-chamber injection device only resulted in improved total cost per dose administered for Benin and Mozambique (at 5.2?cm3and $0.70-per-dose) when the total number of doses administered changed 1% from baseline.ConclusionIn 3 different country supply chains, a single-dose MR dual-chamber injection device would need to be no larger than 5.2?cm3to not significantly impair the flow of other vaccines.
机译:简介与疫苗配对稀释剂,双腔疫苗注射装置简化了在给药前重构疫苗的过程,从而降低了相关的开放小瓶浪费和不良事件。然而,由于这些装置大于电流疫苗小瓶,用于冻干疫苗,制造商需要指导这些设备的规模如何影响疫苗分布和递送。贝宁,比哈尔(印度)的方法产生的Hermes产生的免疫供应链模型。莫桑比克,用单剂量MR双室注射装置更换常规10剂量麻疹 - 风疹(MR)冻干疫苗,测距每剂量(5.2-26〜CM3)和每剂量(0.70美元) ,1.40美元).Resultsat的每剂量为5.2?CM3,双腔注射装置导致类似的疫苗可用性,降低开放的小瓶浪费(OVW),与中等受约束的基线相比施用的类似总成本。供应链。在7.5倍的体积之间,这些器件导致疫苗可用性的降低1%至14%,由于冷链储存利用率增加1%至7%,平均峰值运输利用率增加2%和44%。在最高体积的每剂量,26μm3,疫苗可用性降低9%和14%。在每种情况之间施用每剂量的总成本,因为疫苗采购成本的降低与施用剂量的降低相结合。然而,当施用的剂量总数变化时,介绍了双室注射装置的每剂量每剂量的总成本(以5.2?cm3和0.70-70-70-70-70-70-70-70-70-70-70-70-70-10-70-10.70-70-70-10.70-70-10.70-10-10-10.7美元)。 3不同的国家/地区供应链,单剂量MR双室注射装置需要不大于5.2?CM3不要显着损害其他疫苗的流动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号